quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

WISeKey Reports FY 2025 Preliminary Financial Results

View original at globenewswire.com
WISeKey Reports FY 2025 Preliminary Financial Results WISeKey Reports FY 2025 Preliminary Financial Results Subsidiary SEALSQ Delivers 66% Year-Over-Year Revenue Growth and Advances Global Quantum-Secure Semiconductor Ecosystem Geneva, Switzerland, March 5, 2026– Ad hoc announcement pursuant to Art…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The 58% revenue growth for WISeKey achieved in 2025 and the strong start into 2026 clearly demonstrate the transition of our semiconductor and post-quantum strategy from investment to commercial acceleration

    80% confidence

  • WISeSat upcoming merger with a SPAC is expected to be completed in the first half of 2026

    80% confidence

  • ColibriTD and SEALSQ targeting sub-7nm wafer yield improvement from 50% to 80%

    80% confidence

  • Q1 2026 revenue is expected to exceed $4M, representing over 100% growth versus Q1 2025

    80% confidence

  • Under the NSA's CNSA 2.0 policy, all new National Security Systems must be quantum-resistant by Jan. 1, 2027

    80% confidence

  • WISeKey expects FY 2026 revenue growth of +50% to +100% year-over-year

    80% confidence

  • Initial revenues from QS7001 and QVault TPM expected in late 2026

    80% confidence

  • WISeKey expects to publish its audited full-year financial statements on or before April 30, 2026

    80% confidence

  • WISeKey has over 1.6 billion microchips deployed across various IoT sectors

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
WISeKey Reports FY 2025 Preliminary Financial Results — Source | Via News | pt.VIA.NEWS